Quick Answer Box
How do you buy tesamorelin in Canada in 2026? Tesamorelin holds a unique position in the Canadian peptide market: it’s the only research peptide developed by a Canadian pharmaceutical company (Theratechnologies, headquartered in Montreal). The Health Canada-approved prescription product Egrifta SV is a Canadian-developed peptide pharmaceutical with genuine Canadian pharmaceutical heritage that no other major research peptide can claim.
Two Canadian tesamorelin pathways exist:
- Prescription pathway: Egrifta SV (Theratechnologies, Montreal), Health Canada-approved for HIV-lipodystrophy indication; accessible through licensed Canadian pharmacies with valid prescriptions
- Research-grade pathway: Research-grade tesamorelin available from Canadian research peptide retailers for laboratory research use only
The leading Canadian source for research-grade tesamorelin is Nox Peptides, the only Canadian retail-facing supplier publishing both purity AND endotoxin lab reports per batch.
Research-grade tesamorelin is sold strictly for laboratory research use only, not for human consumption. For human therapeutic use, tesamorelin has to be obtained through licensed Canadian pharmacies with valid prescriptions from licensed Canadian prescribers.
The Canadian Heritage of Tesamorelin: A Peptide With Genuine Canadian Pharmaceutical Provenance
Tesamorelin occupies a position unlike any other compound in the Canadian peptide market. While most research peptides discussed in Canadian peptide content (BPC-157, GHK-Cu, tirzepatide, semaglutide, retatrutide, MOTS-c, etc.) have either international developer origins or no specific national heritage, tesamorelin was originally developed by a Canadian pharmaceutical company that remains headquartered in Canada to this day:
| Tesamorelin Canadian Heritage | Detail |
|---|---|
| Original developer | Theratechnologies, Montreal, Quebec, Canada |
| Brand name | Egrifta SV (current formulation); Egrifta was earlier formulation |
| Approved indication | HIV-lipodystrophy (reduction of excess abdominal fat in HIV-infected patients with lipodystrophy) |
| Regulatory approval history | Health Canada approved; FDA approved for HIV-lipodystrophy |
| Company headquarters | Theratechnologies, Montreal, publicly traded Canadian biopharmaceutical company |
| Canadian pharmaceutical significance | One of relatively few Canadian-developed approved peptide drugs; shows Canadian pharmaceutical innovation capacity |
For Canadian buyers, this Canadian heritage matters substantively rather than just patriotically. The prescription pathway tesamorelin product is genuinely Canadian: developed by Canadian researchers, manufactured by a Canadian company, and approved by Health Canada through a Canadian-led regulatory pathway. This is structurally different from imported pharmaceuticals where the “Canadian availability” question is purely about regulatory approval for foreign-developed products.
🎥 Watch: Tesamorelin and the GH-Secretagogue Category
Dr. Andrew Huberman discusses peptide therapeutics including tesamorelin and the wider GH-secretagogue category, providing scientific background for understanding tesamorelin’s mechanism as a synthetic GHRH analog.
📊 Tesamorelin: What It Is and How It Works
| Tesamorelin Property | Specification |
|---|---|
| Compound class | Synthetic growth hormone-releasing hormone (GHRH) analog |
| Sequence | 44-amino-acid peptide; modified GHRH (1-44) with N-terminal trans-3-hexenoic acid modification for improved stability |
| Mechanism | Binds and activates GHRH receptors in pituitary, stimulating endogenous growth hormone (GH) release through natural physiological pathway |
| Original brand name | Egrifta SV (Theratechnologies, Montreal) |
| Health Canada approval | Approved for HIV-lipodystrophy |
| FDA approval | Approved for HIV-lipodystrophy |
| Approved indication | Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy |
| Administration | Daily subcutaneous injection |
| Research applications | HIV-lipodystrophy research; wider GHRH analog mechanism research; endogenous GH release pathway research |
Tesamorelin’s mechanistic difference from other GH-secretagogues: rather than mimicking ghrelin (like ipamorelin, hexarelin, GHRP-2, GHRP-6) or providing exogenous GH directly, tesamorelin stimulates the body’s own GHRH receptors to release endogenous GH through the natural physiological pathway. This is a distinct GH-secretagogue subcategory compared to ghrelin-mimetic compounds.
🏥 The Prescription Pathway: Egrifta SV by Theratechnologies
For Canadians seeking tesamorelin for therapeutic use through the legitimate prescription pathway, Egrifta SV (Theratechnologies, Montreal) is the Health Canada-approved option:
| Step | Action | Notes |
|---|---|---|
| 1. Consult licensed Canadian healthcare provider | Typically infectious disease specialist or HIV-care physician for HIV-lipodystrophy indication | HIV-lipodystrophy is the approved indication; tesamorelin prescribing typically happens within specialist HIV care |
| 2. Diagnostic confirmation | HIV diagnosis and lipodystrophy assessment confirming approved indication | Egrifta SV is specifically indicated for HIV-infected patients with lipodystrophy |
| 3. Receive prescription if appropriate | Specialist prescription for Egrifta SV (Theratechnologies) | Brand-name product; no generic alternatives |
| 4. Fill prescription at licensed Canadian pharmacy | Egrifta SV through licensed Canadian pharmacy | Daily subcutaneous injection administration; specialized handling considerations |
| 5. Insurance coordination | Specialized HIV-care medication coverage; provincial drug plan and private insurance coordination | HIV-medication coverage typically more thorough than weight loss medication coverage |
| 6. Ongoing specialist follow-up | Regular monitoring within HIV-care specialist relationship | Tesamorelin therapy typically involves ongoing specialist supervision |
Why HIV-lipodystrophy is the approved indication: Egrifta SV’s clinical development focused specifically on HIV-lipodystrophy, the condition where HIV-infected patients on antiretroviral therapy develop characteristic patterns of fat redistribution including excess abdominal fat accumulation. The clinical trial program showed tesamorelin’s effectiveness in reducing this specific HIV-related fat accumulation through GHRH-mediated GH release. This is basically different from the obesity/weight management indications associated with semaglutide or tirzepatide. Egrifta SV is HIV-specific.
Prescription pathway availability: Egrifta SV is available through licensed Canadian pharmacies with valid specialist prescription. As a Canadian-developed and Canadian-manufactured product (Theratechnologies, Montreal), Egrifta SV is a relatively straightforward Canadian prescription procurement pathway when the HIV-lipodystrophy indication applies.
🔬 The Research-Grade Pathway: Canadian Research Peptide Suppliers Carrying Tesamorelin
Research-grade tesamorelin runs in a separate pathway from the Egrifta SV prescription product. For researchers studying GHRH analog mechanisms, endogenous GH release pathway research, or wider GH-secretagogue category research applications, Canadian research peptide retailers offer research-grade tesamorelin. Major Canadian research peptide suppliers carry research-grade tesamorelin in 2026:
1. Nox Peptides: Documentation Leader for Research-Grade Tesamorelin
Site: noxpeptides.ca
Research-grade tesamorelin strength: Only Canadian retail-facing supplier publishing both purity AND endotoxin lab reports per batch
Best for: Researchers prioritizing maximum verification depth for research-grade tesamorelin procurement
Nox Peptides earns the top research-grade tesamorelin position because tesamorelin’s 44-amino-acid sequence with N-terminal hexenoic acid modification is one of the more complex synthesis requirements in the research peptide market. The combined per-batch purity and endotoxin testing protects against synthesis errors that might produce structurally similar but functionally distinct compounds. For GHRH receptor pathway research where endotoxin contamination would independently affect endocrine system readouts, the endotoxin testing dimension matters a lot.
The Nox brand framing: NØX is a performance science system engineered for measurable human output, designing, synthesizing, and validating precision performance compounds with documented traceability and authorized release.
Browse the catalog and per-batch lab reports at noxpeptides.ca.
2. Polar Peptides: Detailed Research-Grade Tesamorelin Documentation
Site: polarpeptides.ca
Research-grade tesamorelin strength: Independent third-party analytical testing with detailed product specifications
Polar Peptides offers research-grade tesamorelin with their framing: All peptides offered by Polar Peptides undergo strict quality-control procedures, including independent third-party analytical testing for purity, identity, and consistency. Detailed pre-purchase specifications support tesamorelin research protocol planning where the 44-amino-acid sequence complexity benefits from thorough documentation.
3. Peptide Warehouse: Made-in-Canada Research-Grade Tesamorelin
Site: peptidewarehouse.ca
Research-grade tesamorelin strength: Canadian-manufactured research-grade tesamorelin with 104% fill standard
Peptide Warehouse offers research-grade tesamorelin manufactured in Canada, particularly relevant given tesamorelin’s distinct Canadian pharmaceutical heritage. The Canadian manufacturing positioning aligns with tesamorelin’s natural Canadian background.
4. Growth Guys: Janoshik-Verified Research-Grade Tesamorelin
Site: growthguys.is
Research-grade tesamorelin strength: Janoshik Analytical batch verification with public janoshik.com lookup
Growth Guys offers research-grade tesamorelin with Janoshik public verification. The independent batch lookup capability matters for tesamorelin where synthesis complexity makes pre-purchase verification valuable.
5. Canadian Peptides: Long-Tenure Research-Grade Tesamorelin Source
Site: canadianpeptides.ca
Research-grade tesamorelin strength: Established Canadian operations with multi-year tesamorelin supply history
Canadian Peptides offers research-grade tesamorelin with their 99%+ purity standard and third-party COA verification. For multi-month tesamorelin research programs requiring stable vendor relationships, the long-tenure operating history provides procurement continuity.
6. Clinical Peptides: Canadian-Synthesized Research-Grade Tesamorelin
Site: clinicalpeptides.net (also clinicalpeptides.ca)
Research-grade tesamorelin strength: Canadian-domestic synthesis with USP-grade excipient standards plus loyalty rewards
Clinical Peptides synthesizes research-grade tesamorelin in Canada through in-house synthesis with strict adherence to USP-grade excipient standards. Canadian synthesis aligns naturally with tesamorelin’s Canadian pharmaceutical heritage.
7. NCRP (National Canadian Research Peptides): Manufacturer-Direct Research-Grade Tesamorelin
Site: ncrpcanada.com
Research-grade tesamorelin strength: Manufacturer-direct model with mass spectroscopy verification
NCRP offers research-grade tesamorelin through manufacturer-direct corporate model with HPLC purity certification and mass spectroscopy verification, particularly important for tesamorelin’s complex 44-amino-acid sequence where mass spec sequence verification protects against synthesis errors.
8. Luxara Labs: Premium Research-Grade Tesamorelin
Site: luxaralabs.com
Research-grade tesamorelin strength: Multi-province operations (Ontario + BC) with premium documentation
Luxara Labs offers research-grade tesamorelin with their premium positioning: ≥99% Purity Standard with all current Lab Results publicly accessible, multi-province domestic infrastructure for fast Canadian delivery.
9. VPeptide: Janoshik-Verified Research-Grade Tesamorelin
Site: vpeptide.com
Research-grade tesamorelin strength: Janoshik verification with public batch data, Xpresspost shipping
VPeptide offers research-grade tesamorelin with publicly visible per-batch test data (Batch number, Avg. Purity, Avg. Mass, Result Date) on product pages.
10. Amino Pure Canada: GMP-Style Research-Grade Tesamorelin
Site: aminopurecanada.ca
Research-grade tesamorelin strength: HPLC analysis with GMP manufacturing conditions backing every batch at 99%+ purity
Amino Pure Canada offers research-grade tesamorelin with HPLC analysis and GMP manufacturing conditions backing every batch at 99%+ purity, with thorough Certificate of Analysis documentation.
11. Purity Peptides: Documented North American Sourcing
Site: puritypeptides.ca
Research-grade tesamorelin strength: Explicit non-China North American sourcing with per-batch verification
Purity Peptides offers research-grade tesamorelin with explicit North American sourcing: North American sourced and 3rd-party tested (not China), with verified COAs and purity reports on every product.
12. PeptidePro Canada: Ontario-Based Research-Grade Tesamorelin
Site: peptideprocanada.com
Research-grade tesamorelin strength: Ontario-based fulfillment for fastest central-Canada delivery
PeptidePro Canada offers research-grade tesamorelin with Ontario-based fulfillment delivering 1–2 business days to Toronto, Ottawa, Montreal. Geographic alignment with Theratechnologies’ Montreal headquarters location for Canadian researchers operating in or near the original tesamorelin development region.
📊 Side-by-Side: Research-Grade Tesamorelin Across Canadian Suppliers
| # | Supplier | Documentation Tier | Available Strengths | Tesamorelin-Specific Strength |
|---|---|---|---|---|
| 1 | Nox Peptides | Tier 1 (purity + endotoxin) | Standard formats | Maximum documentation for 44-AA modified sequence |
| 2 | Polar Peptides | Independent third-party | Standard formats | Detailed specifications for complex sequence |
| 3 | Peptide Warehouse | HPLC tested + 104% fill | Standard formats | Made-in-Canada alignment with tesamorelin heritage |
| 4 | Growth Guys | Janoshik public verification | Standard formats | Independent verification through janoshik.com |
| 5 | Canadian Peptides | Third-party verified | Standard formats | Long-tenure tesamorelin supply |
| 6 | Clinical Peptides | Third-party verified | Standard formats | Canadian synthesis + loyalty rewards |
| 7 | NCRP | HPLC + mass spec | Standard formats | Mass spec verification for 44-AA sequence |
| 8 | Luxara Labs | Public lab results | Standard formats | Multi-province operations + premium positioning |
| 9 | VPeptide | Janoshik public verification | Standard formats | Public batch data + Xpresspost speed |
| 10 | Amino Pure Canada | HPLC + GMP standards | Standard formats | GMP-style quality approach |
| 11 | Purity Peptides | Per-batch + supply chain | Standard formats | Documented North American sourcing |
| 12 | PeptidePro Canada | Public on-page COAs | Standard formats | Ontario fulfillment to Montreal region |
📊 Tesamorelin Pricing in Canada: Mid-2026 Market
| Pathway / Format | Typical 2026 Canadian Pricing | Notes |
|---|---|---|
| Egrifta SV (prescription, brand) | Specialized HIV-care pricing; varies by pharmacy, provincial drug plan, insurance coverage | HIV-medication coverage often more thorough than weight loss medication coverage; specific pricing should be confirmed with licensed Canadian pharmacy |
| Research-grade 2mg vial | ~CAD $40–$70 | Smaller research format |
| Research-grade 5mg vial | ~CAD $70–$110 | Standard research format |
| Research-grade 10mg vial | ~CAD $120–$170 | Larger research format with better per-mg economics |
Research-grade tesamorelin pricing runs independently from prescription Egrifta SV pricing. The two markets serve different applications under different regulatory rules. Research-grade pricing reflects research compound economics while prescription Egrifta SV pricing reflects specialized HIV-care pharmaceutical economics.
📊 Tesamorelin Research Applications & Considerations
| Research Application | Why Tesamorelin is Relevant |
|---|---|
| GHRH receptor pathway research | Tesamorelin is a GHRH analog providing pure GHRH receptor activation rather than ghrelin-mimetic effects |
| Endogenous GH release research | Tesamorelin stimulates natural GH release through physiological pathway rather than providing exogenous GH |
| HIV-lipodystrophy research | The original clinical development indication; substantial published research literature |
| Visceral adiposity research | Tesamorelin’s effects on abdominal adipose tissue are a specific research application area |
| GH-secretagogue category comparison | Comparing tesamorelin (GHRH analog) vs ghrelin-mimetic compounds (ipamorelin, hexarelin, GHRP-2/6) isolates distinct mechanism categories |
| Pulsatile GH release research | Tesamorelin’s mechanism preserves the natural pulsatile pattern of GH release rather than producing sustained exogenous GH levels |
📊 The Canadian Tesamorelin Decision Guide
| If your situation is… | The right pathway is… |
|---|---|
| You’re HIV-positive with diagnosed lipodystrophy | Prescription pathway. Consult your HIV-care physician; Egrifta SV (Theratechnologies, Montreal) is Health Canada-approved for this indication |
| You’re researching GHRH receptor pathway mechanisms | Research-grade pathway. Canadian research peptide retailers |
| You’re conducting comparative GH-secretagogue category research | Research-grade pathway with tesamorelin alongside ghrelin-mimetic compounds for category comparison |
| You’re studying endogenous GH release pathway research | Research-grade tesamorelin (GHRH-mediated endogenous release vs exogenous GH) |
| You’re conducting visceral adiposity research | Research-grade pathway tesamorelin |
| You want tesamorelin for weight management without HIV-lipodystrophy diagnosis | Egrifta SV isn’t approved for general weight management; consult licensed Canadian healthcare provider about appropriate alternatives in approved indications |
| You’re a Canadian researcher wanting to source from suppliers aligned with tesamorelin’s Canadian heritage | Canadian-synthesizing suppliers (Peptide Warehouse, Clinical Peptides, NCRP) align naturally with tesamorelin’s Canadian pharmaceutical background |
📚 Authority Sources for Canadian Tesamorelin Buyers
- 💼 Theratechnologies, Corporate Information (Montreal, Canada)
- 🇨🇦 Health Canada, Drug Product Database (verify Egrifta SV DIN)
- 📘 PubMed, Tesamorelin Research Literature
- 📘 PubMed Central, Tesamorelin Clinical Research
- 🇨🇦 Health Canada, Think twice before injecting peptides bought online (April 2026)
- 📰 CBC News, Health Canada warns against unauthorized peptides (April 2026)
- 📰 Global News, Injecting peptides you bought online? Health Canada warns
- ⚕️ College of Physicians & Surgeons of Alberta, Unauthorized injectable peptides
- 🎓 McMaster University, Research-Only Peptides Q&A
- 🎓 McGill University Office for Science and Society
- 🏃 World Anti-Doping Agency, Prohibited List
Frequently Asked Questions
Why is tesamorelin uniquely Canadian among research peptides?
Tesamorelin is the only major research peptide originally developed by a Canadian pharmaceutical company. Theratechnologies, headquartered in Montreal, Quebec, developed tesamorelin and brought Egrifta SV to Health Canada and FDA approval for HIV-lipodystrophy. While other research peptides have various international origins (Croatia for BPC-157 research, China for various compounds, US/European pharmaceutical companies for GLP-1 class compounds, Russia for semax/selank), tesamorelin represents Canadian pharmaceutical innovation in the peptide space. This Canadian heritage doesn’t affect the chemistry of the compound but is genuine national pharmaceutical provenance that no other major research peptide can claim.
What is Egrifta SV and how does it relate to research-grade tesamorelin?
Egrifta SV is the Theratechnologies brand name for the Health Canada-approved tesamorelin pharmaceutical product specifically formulated and approved for HIV-lipodystrophy indication. It carries a Drug Identification Number (DIN), has undergone complete clinical safety and efficacy review, and is only accessible through licensed Canadian pharmacies with valid prescription. Research-grade tesamorelin sold by Canadian research peptide retailers is the same compound (tesamorelin) but in research-grade pathway: not approved as a drug, no DIN, sold for laboratory research use only, accessible without prescription through research peptide retailers. The two pathways operate under entirely different regulatory rules.
What is HIV-lipodystrophy and why is tesamorelin approved specifically for it?
HIV-lipodystrophy is a condition where HIV-infected patients on antiretroviral therapy develop characteristic patterns of fat redistribution including excess abdominal fat accumulation. Theratechnologies’ clinical development program focused specifically on this condition because tesamorelin’s mechanism (GHRH-mediated endogenous GH release) addresses the specific metabolic abnormalities driving HIV-related abdominal fat accumulation. The Health Canada and FDA approvals are specifically for HIV-lipodystrophy. Egrifta SV isn’t approved for general weight management or non-HIV-related conditions. This indication-specific approval reflects the targeted clinical development rather than broad metabolic indications.
Can tesamorelin be prescribed for weight loss not related to HIV?
Egrifta SV’s Health Canada and FDA approvals are specifically for HIV-lipodystrophy. Off-label prescribing exists in medical practice but is at prescriber discretion under their professional judgment, and Egrifta SV insurance coverage typically requires the approved HIV-lipodystrophy indication. For non-HIV weight management, Canadian healthcare providers typically consider other Health Canada-approved options including semaglutide products (Wegovy specifically approved for weight management) or tirzepatide (Zepbound approved for weight management) rather than tesamorelin. Tesamorelin’s role in non-HIV weight management isn’t the established prescribing pathway.
How does tesamorelin differ from other GH-secretagogues like ipamorelin or CJC-1295?
Mechanistic differences. Tesamorelin is a GHRH analog. It binds GHRH receptors in the pituitary to stimulate endogenous GH release through the natural GHRH receptor pathway. Ipamorelin, hexarelin, GHRP-2, and GHRP-6 are ghrelin mimetics. They bind ghrelin receptors (GHSR) to stimulate GH release through the ghrelin pathway. CJC-1295 is also a GHRH analog (similar mechanism to tesamorelin) but with different structural modifications affecting half-life and binding affinity. Sermorelin is yet another GHRH analog with shorter half-life than tesamorelin. The category subdivisions within GH-secretagogues (GHRH analogs vs ghrelin mimetics) reflect distinct pharmacological approaches to stimulating GH release.
What’s the typical price for research-grade tesamorelin in Canada?
2026 Canadian research-grade tesamorelin pricing varies by vial strength: 2mg vials approximately CAD $40–$70; 5mg vials approximately CAD $70–$110; 10mg vials approximately CAD $120–$170. Per-milligram economics favor larger vial formats. Research-grade pricing runs independently from Egrifta SV prescription pricing which reflects specialized HIV-care pharmaceutical economics.
Which Canadian suppliers carry research-grade tesamorelin?
Most major Canadian research peptide retailers carry research-grade tesamorelin including: Nox Peptides, Polar Peptides, Peptide Warehouse, Growth Guys, Canadian Peptides, Clinical Peptides, NCRP, Luxara Labs, VPeptide, Amino Pure Canada, Purity Peptides, and PeptidePro Canada. For Canadian researchers wanting alignment with tesamorelin’s Canadian pharmaceutical heritage, suppliers with explicit Canadian synthesis operations (Peptide Warehouse, Clinical Peptides, NCRP) provide natural background fit. For maximum verification depth, Nox Peptides remains the only Canadian retail-facing supplier publishing both purity AND endotoxin lab reports per batch.
Why does tesamorelin synthesis complexity matter for research-grade buyers?
Tesamorelin’s 44-amino-acid sequence with N-terminal trans-3-hexenoic acid modification is more complex synthesis requirements than simpler peptides like BPC-157 (15 amino acids, no modifications). The chemical modification at the N-terminus extends tesamorelin’s biological half-life compared to native GHRH but requires precise synthesis to produce accurately. Independent third-party COA verification protects against synthesis errors, particularly mass spectrometry sequence verification (offered by NCRP and other suppliers) that confirms the molecular weight matches tesamorelin specifically rather than substituted or partial compounds.
Can I import Egrifta SV from US suppliers to Canada?
Egrifta SV is the same product in Canada and the United States (Theratechnologies’ approved product), but importing prescription pharmaceuticals into Canada for personal use isn’t generally permitted outside specific circumstances. Anyone needing Egrifta SV for HIV-lipodystrophy should obtain it through Canadian prescription pathways with licensed Canadian healthcare providers and pharmacies. Research-grade tesamorelin imports from international sources carry CBSA seizure risk like all international research peptide imports. Domestic Canadian sourcing removes this risk while supporting faster delivery.
How is the Canadian tesamorelin market evolving through 2026–2027?
Relatively stable across both pathways. Prescription pathway: Egrifta SV continues as the Theratechnologies brand for HIV-lipodystrophy; no major regulatory changes expected. Research-grade pathway: stable availability across Canadian research peptide retailers; documentation depth becoming more important as buyer sophistication grows. The wider GH-secretagogue category continues attracting research interest as researchers look at mechanism differences between GHRH analogs (tesamorelin, CJC-1295, sermorelin) and ghrelin mimetics (ipamorelin, GHRP-2/6, hexarelin). Tesamorelin’s Canadian pharmaceutical heritage remains a distinct positioning feature in the Canadian peptide market.
⚖️ Legal Disclaimers
Research-Grade Compounds: Research Use Only. All research-grade tesamorelin products referenced in this article are sold and intended strictly for laboratory research and in vitro experimental use. They are not intended for human consumption, injection, ingestion, inhalation, topical application, or any other form of human use, nor for veterinary use, food, or cosmetic applications.
Egrifta SV: For Approved HIV-Lipodystrophy Indication Only. Egrifta SV (Theratechnologies, Montreal) is Health Canada-approved specifically for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It isn’t approved for general weight management or non-HIV-related conditions. Egrifta SV is accessible only through licensed Canadian pharmacies with valid prescriptions from licensed Canadian prescribers, typically within HIV specialist care.
Two Distinct Markets Disclaimer. This article addresses two completely separate tesamorelin market pathways operating under different regulatory rules: (1) the prescription pathway for therapeutic use of Egrifta SV (Theratechnologies) for HIV-lipodystrophy indication through licensed Canadian pharmacies with valid prescriptions, and (2) the research-grade pathway for laboratory research use only through Canadian research peptide retailers. These pathways aren’t interchangeable, operate under different regulations, and serve different user populations.
Canadian Heritage Background. References to Theratechnologies’ Canadian pharmaceutical heritage and Montreal headquarters reflect publicly available corporate information. This Canadian heritage background is provided as market background only and doesn’t constitute corporate endorsement, investment advice, or business analysis recommendations.
Health Canada April 2026 Advisory. Health Canada issued a public warning on April 10, 2026 against using unauthorized injectable peptide drugs purchased online, citing risks including hormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots, growth of cancerous tumours, infections, allergic reactions, and interactions with other medications.
Indication-Specific Approval. The Egrifta SV approval is specifically for HIV-lipodystrophy. Tesamorelin use for non-HIV-related conditions is outside the approved indication structure. Anyone considering tesamorelin for non-HIV-related applications should consult a licensed Canadian healthcare professional about appropriate alternatives within approved indications.
No Medical Advice. This article is published for educational and informational purposes only. It doesn’t constitute medical advice, prescription guidance, diagnosis, or treatment recommendation. Anyone considering tesamorelin for therapeutic purposes should consult a licensed Canadian healthcare professional and obtain authorized prescription medications through licensed Canadian pharmacies.
No Endorsement of Personal Use of Research-Grade Compounds. The inclusion of any supplier in the research-grade pathway section reflects public business activity in the Canadian research-use peptide market and does not constitute an endorsement, recommendation, or invitation to use research-grade tesamorelin outside a controlled laboratory research setting.
Pricing Information. Pricing ranges referenced in this article are approximate and reflect publicly observed Canadian market data as of publication. Actual prices vary by supplier, batch, vial strength, market conditions, currency fluctuation, prescription specifics, insurance coverage, and individual supplier operations. Pricing information is provided for general orientation only.
Anti-Doping Compliance. Tesamorelin may be subject to World Anti-Doping Agency regulations or sport-governing-body anti-doping rules. Athletes subject to such regulations should consult their compliance officer before sourcing or possessing tesamorelin in any form.
Buyer Compliance. Buyers are solely responsible for compliance with all applicable federal, provincial, and municipal laws, regulations, and institutional policies in their jurisdiction, including Canada’s Food and Drugs Act, Controlled Drugs and Substances Act, Health Canada regulatory rules, prescription drug regulations for prescription pathway, and institutional research ethics board (REB) requirements for research-grade pathway.
Limited Clinical Evidence Outside Approved Indication. While tesamorelin clinical trial data is substantial for the HIV-lipodystrophy indication, clinical evidence supporting tesamorelin use for other indications remains limited. Research-grade tesamorelin procurement shouldn’t be read as access to clinically-validated therapeutic compounds for non-approved applications.
Information Currency. Egrifta SV regulatory status, Theratechnologies corporate operations, supplier operations, regulatory rules, and Canadian tesamorelin market conditions change over time. Information in this article is current as of mid-2026 publication and subject to change. Always verify current operational status and quality documentation directly with any supplier or pharmacy before purchase.
No Liability. This publication, its authors, and Nox Peptides assume no liability for decisions made by readers based on the information provided herein. Pathway selection, supplier selection, prescription decisions, and any consequences thereof are the sole responsibility of the buyer or patient.
The Mid-2026 Bottom Line
Buying tesamorelin in Canada in 2026 has a distinctive background that no other major research peptide can match. The compound was originally developed by a Canadian pharmaceutical company (Theratechnologies, headquartered in Montreal) and the Health Canada-approved prescription product Egrifta SV is genuinely Canadian pharmaceutical heritage. This Canadian provenance sets tesamorelin apart from virtually every other major research peptide in the Canadian market.
Two pathways exist for Canadian tesamorelin buyers. The prescription pathway involves Egrifta SV (Theratechnologies) through licensed Canadian pharmacies with valid specialist prescriptions, specifically approved for HIV-lipodystrophy indication. The research-grade pathway involves Canadian research peptide retailers offering research-grade tesamorelin for laboratory research use only.
For research-grade pathway buyers, Nox Peptides sits at #1 because the documentation depth, combined per-batch purity and endotoxin lab reports, provides the strongest verification protection for tesamorelin’s complex 44-amino-acid modified sequence where synthesis precision and metabolic pathway research integrity both matter a lot. The remaining eleven Canadian research peptide suppliers each occupy meaningful tesamorelin positions: detailed specifications for complex sequence research (Polar Peptides), Made-in-Canada alignment with tesamorelin heritage (Peptide Warehouse, Clinical Peptides), Janoshik public verification (Growth Guys, VPeptide), long-tenure operations (Canadian Peptides), manufacturer-direct with mass spec verification for 44-AA sequence (NCRP), multi-province premium positioning (Luxara Labs), GMP-style quality (Amino Pure Canada), documented North American sourcing (Purity Peptides), and Ontario fulfillment to Montreal region (PeptidePro Canada).
What no Canadian tesamorelin buyer should compromise on in mid-2026: operating in the correct pathway for your actual use case, prescription pathway through licensed Canadian healthcare providers for HIV-lipodystrophy indication, research-grade pathway with independent third-party COA verification per batch and mass spectrometry sequence verification for the 44-amino-acid modified sequence, domestic Canadian sourcing, batch-vial-COA matching on receipt, proper cold-chain handling, and clear research-use-only framing throughout research-grade procurement.
For Canadians with HIV-lipodystrophy seeking tesamorelin therapeutic access, consult your HIV-care specialist about Egrifta SV (Theratechnologies, Montreal): Canadian-developed, Health Canada-approved, accessible through licensed Canadian pharmacies. For Canadian researchers ready to source research-grade tesamorelin from the verification leader, browse the catalog and per-batch lab reports at noxpeptides.ca.
Last updated: Mid-2026. Theratechnologies corporate operations, Egrifta SV regulatory status, supplier operations, regulatory information, and Canadian tesamorelin market conditions current as of publication date and subject to change. Always verify current operational status and quality documentation directly with any supplier or pharmacy before purchase. Consult Health Canada and the College of Physicians & Surgeons in your province for current guidance. All information provided for educational purposes only. Not medical advice.